Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: Multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival

References

• Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Progress of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28: 1687–95.
   PubMed Web of Science ®Google Scholar
• Dusheiko GM. The natural course of chronic hepatitis C: implications for clinical practice. J Viral Hepatol 1998;Suppl 1:9–12.
   Google Scholar
• Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28:930–8.
   PubMed Web of Science ®Google Scholar
• Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228–33.
   Google Scholar
• Akuta N, Chayama K, Suzuki F, Someya T, Kobayashi M, Tsubota A, et al. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2 (TAP2) *0201 allele. J Med Virol 2001;64:109–16.
   PubMed Web of Science ®Google Scholar
• Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Group. N Engl J Med 1989;321:1501–6.
   Google Scholar
• Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, doubleblind, placebo-controlled trial. N Engl J Med 1989;321: 1506–10.
   Google Scholar
• Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003;38:493–502.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998;129:94–9.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124–30.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk of hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174–81.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483–91.
   PubMed Web of Science ®Google Scholar
• Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051–5.
   PubMed Web of Science ®Google Scholar
• Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141–7.
   PubMed Web of Science ®Google Scholar
• Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alpha- 2b versus no treatment. Hepatology 1999;29:1870–5.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European concerted action on viral hepatitis. J Hepatol 1997;27:201–5.
   Google Scholar
• Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593–602.
   PubMed Web of Science ®Google Scholar
• Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435–40.
   PubMed Web of Science ®Google Scholar
• Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901–9.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–72.
   PubMed Web of Science ®Google Scholar
• Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, Magalotti D, et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001;48:843–8.
   PubMed Web of Science ®Google Scholar
• Haydon GH, Jarvis LM, Blair CS, Simmonds P, Harrison DJ, Simpson KJ, et al. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut 1998;42:570–5.
   PubMed Web of Science ®Google Scholar
• Simmonds P. Clinical relevance of hepatitis C virus genotypes. Gut 1997;40:291–3.
   PubMed Web of Science ®Google Scholar
• Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299–305.
   PubMed Web of Science ®Google Scholar
• Mahaney K, Tedeschi V, Maertens G, Di Bisceglie AM, Vergalla J, Hoofnagle JH, et al. Genotypic analysis of hepatitis C virus in American patients. Hepatology 1994;20: 1405–11.
   PubMed Web of Science ®Google Scholar
• Tsubota A, Chayama K, Ikeda K, Arase Y, Koida I, Saitoh S, et al. Factors predictive of response to interferon-a therapy in hepatitis C virus infection. Hepatology 1994;19:1088–94.
   PubMed Web of Science ®Google Scholar
• Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339: 1543.
   Google Scholar
• Akuta N, Suzuki F, Tsubota A, Suzuki Y, Someya T, Kobayashi M, et al. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as a consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 2002;37:831–6.
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Tsubota A, Suzuki Y, Someya T, Kobayashi M, et al. Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy. J Med Virol 2003;69:376–83.
   PubMed Web of Science ®Google Scholar
• Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Suzuki Y, et al. Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course. J Gastroenterol 2000;35:607–12.
   PubMed Web of Science ®Google Scholar
• Chayama K, Tsubota A, Arase Y, Saitoh S, Koida I, Ikeda K, et al. Genotypic subtyping of hepatitis C virus. J Gastroenterol Hepatol 1993;8:150–6.
   PubMed Web of Science ®Google Scholar
• Desmet VJ, Gerber M, Hoofnagle JH, Manna M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–20.
   PubMed Web of Science ®Google Scholar
• Hino K, Okita K. Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C. J Antimicrobial Chemother 2004;53:19–22.
   PubMed Web of Science ®Google Scholar
• Hino K, Kitase A, Satoh Y, Fujiwara D, Yamaguchi Y, Korenaga M, et al. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepatitis 2002;9:370–6.
   PubMed Web of Science ®Google Scholar
• Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999;86: 589–95.
   PubMed Web of Science ®Google Scholar
• Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494–500.
   PubMed Web of Science ®Google Scholar
• Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 1999;30:653–9.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000;87:741–9.
   PubMed Web of Science ®Google Scholar
• Reichard O, Norkrans G, Fryden A, Braconier JH, Sonner-borg A, Weiland O. Randomised, double-blind, placebocontrolled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351: 83–7.
   Google Scholar
• Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352: 1426–32.
   Google Scholar
• McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485–92.
   Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666–72.
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958–65.
   PubMed Web of Science ®Google Scholar
• Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395–403.
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy K, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
   Google Scholar
• Van Vlierberghe H, Delanghe JR, De Vos M, Leroux-Roel G. The members of the BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001;34: 911–6.
   Google Scholar